Nephrology & Urology Clinical Trials

Statistical methods in nephrology & urology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All nephrology & urology trials

489 results

• NRRIndependent statistical analysis of Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 23NCT00225420
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 19NCT05714553
• Nutraceutical Efficacy for rUTI: Complete Statistical AnalysisIndependent statistical analysis of Nutraceutical Efficacy for rUTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395288).Phase 2/3Results postedn = 61NCT03395288
• Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03570476).Phase 2Results postedn = 2NCT03570476
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 35NCT00950911
• Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 26NCT05678322
• Oral Calcitriol With Ketoconazole in CRPC: Complete Statistical AnalysisIndependent statistical analysis of Oral Calcitriol With Ketoconazole in CRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03261336).Phase 2Results postedn = 1NCT03261336
• Oral Paricalcitol in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Oral Paricalcitol in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00587158).Phase NAResults postedn = 100NCT00587158
• Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women: Complete Statistical AnalysisIndependent statistical analysis of Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,671NCT03354598
• OrBITIndependent statistical analysis of Overactive Bladder Innovative Therapy Trial (OrBIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00448175).Phase 4Results postedn = 100NCT00448175
• Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01866423).Phase 2Results postedn = 4NCT01866423
• Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: Complete Statistical AnalysisIndependent statistical analysis of Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00535301).Phase 4Results postedn = 75NCT00535301
• Over Active Bladder Patients Having Sling Surgery: Complete Statistical AnalysisIndependent statistical analysis of Over Active Bladder Patients Having Sling Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00852696).Phase NAResults postedn = 1NCT00852696
• Overnight Pant Study for Children With Nocturnal Enuresis: Complete Statistical AnalysisIndependent statistical analysis of Overnight Pant Study for Children With Nocturnal Enuresis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05178641).Phase NAResults postedn = 32NCT05178641
• Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 63NCT01042522
• Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).Phase 2Results postedn = 31NCT00006227
• PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 56NCT00596635
• Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01392183).Phase 2Results postedn = 69NCT01392183
• PBroCIndependent statistical analysis of Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01265953).Phase NAResults postedn = 98NCT01265953
• PCMH-KDIndependent statistical analysis of Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02270515).Phase NAResults postedn = 175NCT02270515
• Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434330).Phase 2Results postedn = 91NCT00434330
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 129NCT03260894
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).Phase 2Results postedn = 16NCT00491075
• Penile Nerve Stimulation for Treatment of Delayed Ejaculation: Complete Statistical AnalysisIndependent statistical analysis of Penile Nerve Stimulation for Treatment of Delayed Ejaculation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04115540).Phase NAResults postedn = 20NCT04115540
• PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).Phase NAResults postedn = 713NCT01293799
• Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 22NCT03812679
• Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 73NCT01709227
• PERTINENCEIndependent statistical analysis of Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase EARLY_1Results postedn = 6NCT04897763
• PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205646).Phase NAResults postedn = 11NCT01205646
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).Phase 1Results postedn = 49NCT03685591
• Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 6NCT02054572
• Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 20NCT01430169
• Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 32NCT03311841
• Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 12NCT01254396
• Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 33NCT02011490
• PHASEIndependent statistical analysis of Effects of Sulforaphane on Normal Prostate Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00946309).Phase 1/2Results postedn = 45NCT00946309
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 17NCT02901548
• Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 6NCT00124917
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 252NCT02608268
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 61NCT02348008
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 5NCT00630409
• Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 51NCT02212197
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 304NCT01037790
• Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02217709).Phase 2Results postedn = 26NCT02217709
• Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced – Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay: Complete Statistical AnalysisIndependent statistical analysis of Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 7NCT05811377
• Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 151NCT00540124
• Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 20NCT02282930
• Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 10NCT04733664
• PLANET 1Independent statistical analysis of Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 353NCT00296374

← All therapeutic areas